drugset / Trial / NCT05202275
The Optimization of Antiemetic Regimen for C-RINV in LA-HNSCCs
NaSingle-groupOpen-labelTreatment
Summary
This study sought to investigate the efficacy and safety of a three-drug combination antiemetic regimen of olanzapine combined with aprepitant and palonosetron for the prevention of chemoradiotherapy-induced nausea and vomiting in locally advanced head and neck squamous cell carcinoma.
Timeline
- Start
- 2020-12-01
- Primary completion
- 2022-12
- Completion
- 2023-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Aprepitant | Other / unclassified | 80 mg | Oral |
| Subject | Olanzapine | Small molecule | 10 mg | Oral |
| Subject | Palonosetron | Other / unclassified | 0.25 mg | Intravenous |